Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2025)

Amphastar Pharmaceuticals (AMPH) has 6 years of Long-Term Investments data on record, last reported at $13.3 million in Q3 2025.

  • For Q3 2025, Long-Term Investments rose 41.49% year-over-year to $13.3 million; the TTM value through Sep 2025 reached $13.3 million, up 41.49%, while the annual FY2024 figure was $10.3 million, 51.47% up from the prior year.
  • Long-Term Investments reached $13.3 million in Q3 2025 per AMPH's latest filing, up from $12.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $15.2 million in Q1 2024 and bottomed at $1.5 million in Q2 2023.
  • Average Long-Term Investments over 5 years is $6.5 million, with a median of $4.5 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: surged 900.0% in 2021, then tumbled 52.3% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $3.4 million in 2021, then soared by 32.35% to $4.5 million in 2022, then soared by 51.11% to $6.8 million in 2023, then surged by 51.47% to $10.3 million in 2024, then increased by 29.13% to $13.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $13.3 million in Q3 2025, $12.1 million in Q2 2025, and $10.6 million in Q1 2025.